Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN

Valerio De Stefano, Elena Rossi, Tommaso Za, Elisabetta Antonioli, Paola Guglielmelli, Lisa Pieri, Mariachiara Finazzi, Elisa Rumi, Vincenzo Martinelli, Nicola Vianelli, Maria Luigia Randi, Irene Bertozzi, Marco Ruggeri, Elena Elli, Rossella Cacciola, Emma Cacciola, Enrico Pogliani, Francesco Rodeghiero, Michele Baccarani, Francesco PassamontiGuido Finazzi, Alessandro Rambaldi, Alberto Bosi, Mario Cazzola, Tiziano Barbui, Alessandro M. Vannucchi

Risultato della ricerca: Contributo in rivistaArticolo in rivista

78 Citazioni (Scopus)

Abstract

Hydroxyurea (Hydroxycarbamide; HU) is commonly used for the long-term treatment of patients with Philadelphia-chromosome negative chronic myeloproliferative neoplasms (MPNs). It is considered a first-choice agent for the treatment of these disorders as underlined by the European Leukemia Net Consensus Conference [1], although it is formally approved for this indication in some countries only. The drug is reportedly well tolerated in the large majority of subjects, although systemic and/or localized toxicities have been reported. Consensus criteria for definition of "intolerance" to HU have been described;patients who develop intolerance are candidate for second-line therapy and, more recently, for investigational drugs. However, no epidemiologic information about the occurrence of the most clinically significant HU-associated adverse events is yet available. In this study, the authors report on a multicenter series of 3,411 patients who were treated with HU among which 184, accounting for 5% of total, developed significant drug-related toxicities. These data provide an estimate of the frequency and a detailed characterization of clinically significant HU-related toxicities; these information have relevance for the management of MPN patients who require second-line therapy after developing HU-related intolerance.
Lingua originaleEnglish
pagine (da-a)552-554
Numero di pagine3
RivistaAmerican Journal of Hematology
Volume87
DOI
Stato di pubblicazionePubblicato - 2012

Keywords

  • MYELOPROLIFERATIVE NEOPLASM

Fingerprint

Entra nei temi di ricerca di 'Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN'. Insieme formano una fingerprint unica.

Cita questo